Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Nature cancer·2026
Same author

Risk score for esophageal and gastric cancer in the over 50-year-old population based on self-reported information -the RISC-GAP project.

BMC gastroenterology·2026
Same author

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

BMC medical research methodology·2026
Same author

Polypharmacy Among 200 000 Subjects of the Population-Based German National Cohort Study (NAKO), Aged 19-74: A Baseline Analysis.

Deutsches Arzteblatt international·2026
Same author

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
Same author

Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.

BMC medicine·2026
Same journal

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same journal

Cardiac Risk After Heart-Sparing Breast Radiotherapy.

JAMA oncology·2026
Same journal

When Not to Push the Boulder.

JAMA oncology·2026
Same journal

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.

JAMA oncology·2026
Same journal

Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer.

JAMA oncology·2026
Same journal

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer.

Jie Ding1,2, Dominic Edelmann3, Sigrid V Carlsson1,4

  • 1Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center, Heidelberg, Germany.

JAMA Oncology
|May 14, 2026
PubMed
Summary
This summary is machine-generated.

Modifiable risk factors for pancreatic cancer (PC) pose a greater risk in younger adults, particularly those with high genetic predisposition. Early intervention is crucial for high-genetic-risk individuals to mitigate PC development.

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Related Experiment Videos

Last Updated: May 16, 2026

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Area of Science:

  • Oncology
  • Genetics
  • Epidemiology

Background:

  • Identifying individuals at high risk for pancreatic cancer (PC) is essential for targeted prevention.
  • The interplay between genetic predisposition and modifiable lifestyle factors in PC risk requires further investigation across different age groups.

Purpose of the Study:

  • To examine if the association between modifiable risk factors and PC risk differs based on genetic risk profiles and age.
  • To inform early-stage prevention strategies for pancreatic cancer.

Main Methods:

  • A prospective population-based cohort study utilizing UK Biobank data from 290,645 participants.
  • Assessed polygenic risk score (PRS) and modifiable risk score (MRS) for PC, categorizing them into low, intermediate, and high strata.
  • Hazard ratios (HRs) and standardized 10-year cumulative incidences (SCI) were calculated to evaluate associations across age groups (<60, 60-69, ≥70 years).

Main Results:

  • Pancreatic cancer risk was consistently associated with higher PRS across all age groups.
  • Modifiable risk factors (MRS) showed a stronger association with PC risk in younger participants (age <60) compared to older groups.
  • The highest 10-year cumulative incidence of PC was observed in younger individuals with both high PRS and high MRS.

Conclusions:

  • The impact of modifiable risk factors on pancreatic cancer risk is most pronounced in younger adults, especially those with a high genetic risk.
  • These findings underscore the importance of early-life interventions and risk factor modification for individuals with high genetic susceptibility to pancreatic cancer.